
Celcuity, Inc. (NASDAQ:CELC – Free Report) – Analysts at HC Wainwright dropped their FY2026 EPS estimates for Celcuity in a research report issued on Monday, November 9th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($5.23) per share for the year, down from their previous forecast of ($4.84). HC Wainwright currently has a “Buy” rating and a $150.00 target price on the stock. The consensus estimate for Celcuity’s current full-year earnings is ($5.08) per share. HC Wainwright also issued estimates for Celcuity’s Q4 2026 earnings at ($1.50) EPS, Q1 2027 earnings at ($1.30) EPS, Q2 2027 earnings at ($1.17) EPS, Q3 2027 earnings at ($0.73) EPS, Q4 2027 earnings at ($0.67) EPS, FY2027 earnings at ($3.87) EPS, FY2028 earnings at ($1.38) EPS, FY2029 earnings at $1.32 EPS and FY2030 earnings at $4.00 EPS.
A number of other equities analysts also recently issued reports on CELC. Citizens Jmp reissued a “market outperform” rating and set a $177.00 target price on shares of Celcuity in a research note on Monday, August 17th. JPMorgan Chase & Co. assumed coverage on Celcuity in a report on Thursday, September 17th. They issued an “overweight” rating and a $157.00 price target for the company. Needham & Company LLC decreased their price target on Celcuity from $140.00 to $134.00 and set a “buy” rating on the stock in a research note on Wednesday, September 30th. Wall Street Zen raised Celcuity from a “strong sell” rating to a “sell” rating in a report on Saturday, November 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celcuity in a report on Tuesday, September 1st. Thirteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $151.79.
Celcuity Stock Performance
Shares of CELC opened at $56.31 on Wednesday. Celcuity has a twelve month low of $53.54 and a twelve month high of $151.02. The stock’s 50 day moving average is $69.79 and its two-hundred day moving average is $97.15. The company has a quick ratio of 14.59, a current ratio of 14.62 and a debt-to-equity ratio of 6.04.
Celcuity (NASDAQ:CELC – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($1.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.51) by $0.30.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in CELC. Soleus Capital Management L.P. acquired a new stake in shares of Celcuity during the 3rd quarter valued at approximately $133,813,000. Assenagon Asset Management S.A. boosted its stake in shares of Celcuity by 685.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,478,607 shares of the company’s stock worth $117,579,000 after acquiring an additional 1,290,466 shares in the last quarter. Bank of America Corp DE acquired a new stake in shares of Celcuity in the 2nd quarter worth approximately $153,928,000. Wellington Management Group LLP grew its holdings in shares of Celcuity by 111.4% in the 2nd quarter. Wellington Management Group LLP now owns 906,595 shares of the company’s stock worth $94,848,000 after acquiring an additional 477,643 shares during the period. Finally, Apis Capital Advisors LLC grew its holdings in shares of Celcuity by 5.4% in the 3rd quarter. Apis Capital Advisors LLC now owns 567,200 shares of the company’s stock worth $45,104,000 after acquiring an additional 29,200 shares during the period. 63.33% of the stock is currently owned by institutional investors and hedge funds.
Recent Celcuity Headlines
These are some of the CELC headlines that stood out recently:
- Positive Sentiment: Zacks Research upgraded Celcuity from “strong sell” to “hold,” a more favorable view that may provide modest support. Zacks Research ratings
- Positive Sentiment: HC Wainwright raised its Q3 2027 EPS forecast to a loss of $0.73 per share from a loss of $0.80, while maintaining its Buy rating and $150 price target. Celcuity analyst estimates
- Negative Sentiment: HC Wainwright cut EPS estimates for several periods, including FY2026 to a loss of $5.23 per share, FY2027 to a loss of $3.87, and FY2028 from expected earnings of $0.92 to a loss of $1.38. Its forecasts for FY2029 and FY2030 were also reduced substantially, though they remain profitable. These revisions suggest a longer path to earnings than previously expected. Celcuity analyst estimates
About Celcuity
Celcuity is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company uses its CELsignia platform to analyze signaling activity in tumor cells and identify patients who may be more likely to respond to treatments aimed at specific cellular pathways. Its drug-development program includes gedatolisib, a therapy designed to inhibit PI3K and mTOR signaling pathways. Celcuity is studying the drug in clinical trials for breast cancer and other solid tumors, with a focus on treatment strategies tailored to tumor biology.
Read More
- Five stocks we like better than Celcuity
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.
